Compare MSBI & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | EVO |
|---|---|---|
| Founded | 1881 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 700.0M | 778.3M |
| IPO Year | 2011 | 2007 |
| Metric | MSBI | EVO |
|---|---|---|
| Price | $33.33 | $1.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $24.33 | $7.00 |
| AVG Volume (30 Days) | ★ 114.7K | 41.1K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.41 | $1.37 |
| Revenue Next Year | $2.07 | $10.05 |
| P/E Ratio | $21.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.24 | $1.80 |
| 52 Week High | $35.10 | $4.27 |
| Indicator | MSBI | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 34.99 |
| Support Level | $33.04 | N/A |
| Resistance Level | $35.10 | $1.97 |
| Average True Range (ATR) | 0.75 | 0.03 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 61.69 | 13.68 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.